EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series

Xueying Chen, Zhaohui Wang, Xuejie Wang, Qinjie Weng, Xiaonong Chen, Jingyuan Xie, Zijin Chen

Kidney Diseases · 24.04.2026 · 12 (1) · 464-472

DOI: 10.1159/000552150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney Diseases, online erschienen am 24.04.2026. Verfasst von Xueying Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Treatment options for IgA nephropathy (IgAN) patients with severe renal impairment are limited. Although telitacicept is approved for reducing proteinuria in IgAN, prior trials excluded patients with estimated glomerular filtration rate (eGFR) 1 g/day who received ≥24 weeks of telitacicept between March 2023 and June 2024. Proteinuria, eGFR, and serum immunoglobulins were assessed longitudinally.

Results

Thirteen patients were included. Proteinuria decreased by 45% at month 6 and remained reduced by 51%, 47%, and 45% at months 12, 18, and 24, respectively. One patient initiated dialysis at month 15. Mean eGFR remained stable over 24 months, with an annual decline slope of −2.39 mL/min/1.73 m2/year. In 8 patients, serum IgA fell from 2.93 ± 0.78 to 0.78 ± 0.28 g/L (p = 0.001) and IgG from 11.16 ± 2.92–6.53 ± 2.85 g/L (p < 0.001) at month 6, both stable through month 12. Combination therapy with glucocorticoids achieved greater proteinuria reductions at months 1–6 and a more favorable eGFR slope (+0.95 ± 6.37 vs. −3.88 ± 3.76 mL/min/1.73 m2/year) than monotherapy.

Conclusion

Telitacicept reduced proteinuria and stabilized eGFR in IgAN patients with severe renal impairment. It may be a therapeutic option for patients unresponsive or intolerant to conventional therapy, but confirmation in larger, prospective studies is warranted.

Schlagwörter

Stichwörter der Autor:innen

IgA nephropathyProteinuriaSafetySevere renal impairmentTelitacicept

Autor:innen und Institutionen

  • Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
  • Department of Nephrology, Wuxi Branch of Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Wuxi, China.
  • Department of Nephrology, Luwan Branch of Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

Zitieren

APA

Chen, X., Wang, Z., Wang, X., Weng, Q., Chen, X., Xie, J., & Chen, Z. (2026). Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series. Kidney Diseases, 12(1), 464-472. https://doi.org/10.1159/000552150

Vancouver

Chen X, Wang Z, Wang X, Weng Q, Chen X, Xie J, et al. Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series. Kidney Diseases. 2026;12(1):464-472. doi:10.1159/000552150

BibTeX
@article{Chen2026,
  author = {Chen, Xueying and Wang, Zhaohui and Wang, Xuejie and Weng, Qinjie and Chen, Xiaonong and Xie, Jingyuan and Chen, Zijin},
  title = {Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series},
  journal = {Kidney Diseases},
  year = {2026},
  volume = {12},
  number = {1},
  pages = {464--472},
  doi = {10.1159/000552150}
}
Kostenlos starten →